Feedback / Questions
Idafang (ivonescimab) - Summit Therapeutics
https://www.businesswire.com/news/home/20260913549808/en/Ivonescimab-Monotherapy-Demonstrates-a-Statistically-Significant-Clinically-Meaningful-Benefit-Compared-to-Pembrolizumab-Monotherapy-in-PD-L1-Positive-Advanced-NSCLC-in-Akesos-HARMONi-2-Study-Conducted-in-China
Sep 13, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next